

Ref: BHL/STEX 54/2025-26

Date: December 31, 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051
Scrip Code: 539872	Symbol: BAJAJHCARE

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Dear Sir/Madam,

This is in reference to our earlier intimation dated October 04, 2025, regarding the recommendation received from Subject Expert Committee (SEC) (Neurology & Psychiatry) of Central Drugs Standard Control Organisation (CDSCO) for conducting Phase III clinical trials for Suvorexant Tablets.

We hereby inform you that the Company has received approval from CDSCO today, i.e. December 31, 2025, to conduct Clinical Trial and Bioequivalence Study of Suvorexant Tablets.

The brief details, in accordance with the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed as “Annexure-I”.

Kindly take the same on record.

Thanking You,

**For and Behalf of Board of Director of
Bajaj Healthcare Limited**

**Monica Tanwar
Company Secretary & Compliance Officer**

Encl: as above

Annexure-I

Details required under the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No	Particulars	Remarks
a)	Name of the regulatory or licensing authority	Central Drugs Standard Control Organisation (CDSCO)
b)	Brief details of the approval/ license obtained/ withdrawn/ surrendered	Approval received from CDSCO to conduct Clinical Trial and Bioequivalence Study of Suvorexant Tablets.
c)	Impact/relevance of such approval/license to the listed entity	Enables the Company to conduct Clinical Trial and Bioequivalence Study of Suvorexant Tablets
d)	Withdrawal/cancellation or suspension of licence/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any	Not Applicable
e)	Period for which such approval/license is/was valid	Not Applicable
f)	The actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval.	Not Applicable